ClinicalTrials.gg
CompletedNCT02654860Updated Oct 27, 2021Results posted

Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia

A Phase 1/2 interventional study of Paracetamol 3% and Placebo injection containing Saline solution 0.9% in Phase 1: Pain Management and Phase 2: Pain Management, sponsored by Sintetica SA. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-27.

Sponsored by Sintetica SA · Phase 1/2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
86th of 137
69 · median 95
Started
2016
with 8 others
Phase 1/2
2 of 137
none open now
Registered
86th of 137
by date

Among the 137 studies testing acetaminophen in Pain, this one is the 86th largest by enrollment, is one of 9 that started in 2016, is one of 2 in phase 1/2, and was the 86th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

Two-part study of intrathecal paracetamol administered immediately before spinal anaesthesia in patients scheduled for hip replacement surgery

Read the detailed description

This is a prospective, single centre, two-part, three doses study. Part 1 is a Phase I, three cohorts, dose-ascending, open-label, safety study. Part 2 is a Phase II, randomised, parallel-group, double-blind, placebo-controlled, exploratory efficacy and safety study The objective of the study is to investigate the efficacy and safety of a single intrathecal injection of paracetamol, administered at 3 doses to 3 active treatment groups, as compared to placebo solution, for post-operative analgesia of hip replacement surgery performed under spinal anaesthesia. Patients scheduled for hip replacement surgery will be randomised into 4 treatment groups (15 patients per group) to receive either one of the 3 single doses of paracetamol 3% (D1: 60 mg, D2: 90 mg, D3: 120 mg) or placebo solution (P: saline solution) by intrathecal (IT) injection. Immediately after paracetamol or placebo IT administration, all patients will receive a single IT dose of Hyperbaric Bupivacaine HCl 0.5% (12.5 mg for ≤ 160 cm-tall patients and 15 mg for > 160 cm-tall patients). The time interval between paracetamol IT and bupivacaine IT administrations should not exceed 2 min.

The study will include a screening phase (Visit 1, Days -21/1), a treatment phase (paracetamol IT administration, anaesthesia and surgical procedure: Visit 2, Day 1) and a follow-up phase including an observation period (Visit 3, from Day 1 after surgery until discharge, a final visit (at discharge) and a follow-up (day 6±1). Pain at rest will be assessed at screening and on visit 2 at baseline (0 h), 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 and 48 h after anaesthetic IT injection and at discharge, using a 0-100 mm VAS.

03

Conditions studied

  • Phase 1: Pain Management
  • Phase 2: Pain Management

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : signed written informed consent before inclusion in the study
  • Sex, age and surgery: male/female 18-80 years (inclusive) old patients, scheduled for hip replacement surgery, with anticipated need for post-operative narcotic analgesia, adequate i.v. access and anticipated hospital stay > 48 hours.
  • (BMI): 18 - 34 kg/m2 inclusive
  • : I-III
  • Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study
  • Inclusion criteria - Phase 1 only : Age: 18-70 (inclusive) old patients
  • Inclusion criteria - Phase 2 only : Age: 18-80 (inclusive) old patients Hospital stay: Patients with anticipated hospital stay > 48 hours

Exclusion criteria

Exclusion Criteria Phase 1 and Phase 2:

  • Physical findings: abnormal physical findings which could interfere with the objectives of the study. to spinal anaesthesia. History of neuromuscular diseases to the lower extremities
  • : IV-V
  • Further anaesthesia: patients expected to require further anaesthesia
  • Pain assessment: anticipated to be unable to make a reliable self-report of pain intensity
  • Allergy: ascertained or presumptive to the active principles (paracetamol and/or amide type anaesthetics) and/or formulations' ingredients or related drugs, opioids, non-steroidal anti-inflammatory drugs; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers could affect the outcome of the study
  • Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric and neurological diseases, sepsis, blood coagulation disorders, severe cardiopulmonary disease, thyroid disease, diabetes, other neuropathies, history or evidence of asthma or heart failure. History of severe head trauma that required hospitalisation, intracranial surgery or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurism or CNS mass lesion.
  • Liver function: Impaired liver function (transaminases > twice upper limit)
  • Renal function: Renal dysfunction (creatinine > 2.0 mg/dL)
  • Investigative drug studies: participation in the evaluation of any product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study
  • Drug, alcohol: history of drug or alcohol abuse. Pre-existing dependence on narcotics or known tolerance to opioids
  • Pregnancy and lactation: positive pregnancy test at screening (if applicable), pregnant or lactating women [The pregnancy test will be performed to all fertile women and to all women up to 55 years old, if not in proven menopause (available laboratory test confirming menopause or surgically sterilised)]
  • Chronic pain syndromes: patients with chronic pain syndromes (taking opioids, anticonvulsant agents or chronic analgesic therapy).
  • Medications: medication known to interfere with the extent of spinal blocks for 2 weeks before the start of the study. Paracetamol formulations, other than the investigational product, for 1 week before the start of the study and during the study. Hormonal for females are allowed.
  • Phase 2 only - Exclusion criteria Pain assessment: anticipated to be unable to make a reliable self-report of pain intensity
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    60 mg Paracetamol 3% (2 mL)

    60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.

    Drug: Paracetamol 3% · Drug: Hyperbaric Bupivacaine HCl 0.5%

  • Experimental
    90 mg Paracetamol 3% (3 mL)

    90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.

    Drug: Paracetamol 3% · Drug: Hyperbaric Bupivacaine HCl 0.5%

  • Experimental
    120 mg Paracetamol 3% (4mL)

    120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.

    Drug: Paracetamol 3% · Drug: Hyperbaric Bupivacaine HCl 0.5%

  • Placebo comparator
    Phase II Only: Saline solution 0.9%

    Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.

    Drug: Placebo injection containing Saline solution 0.9% · Drug: Hyperbaric Bupivacaine HCl 0.5%

Interventions

  • Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery

  • DrugPlacebo injection containing Saline solution 0.9%

    Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.

  • DrugHyperbaric Bupivacaine HCl 0.5%

    NIMP, spinal anaesthetic before the surgical procedure

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol

    Phase 1: Number of participants with treatment evaluation and confirmation of the safety of the three doses of paracetamol 3% solution administered in the total number of patients enrolled

    Time frame: In the first 24 hours, in the first 48 hours and at day 7±1

  2. Phase 2: Pain Intensity

    Phase 2: Pain intensity at rest evaluated as VAS scores ( 0-100 mm visual analogue scale : 0 is the absence pain and 100 is the maximum pain sensation)

    Time frame: baseline (0 h), 1, 6, 9, 12, 15, 24, and 48 h after anaesthetic IT injection and at discharge

Secondary outcomes

  1. Phase 2: Morphine

    Phase 2: Total morphine use

    Time frame: At 24 and 48 h after anaesthetic IT injection and entire study period, up to 7 days

  2. Phase 2: Time to First Morphine Use

    Phase 2: Time to first morphine use (minutes)

    Time frame: Postoperative, up to 48 hours after end of surgery

  3. Phase 2: Number of Participants With Need for Supplemental Analgesia

    Phase 2: Need for supplementary analgesia, other than the planned morphine PCA

    Time frame: Postoperative, up to 48 hours after end of surgery

  4. Phase 2: Morphine-related Adverse Events

    Percentage of subjects experiencing during the study the morphine-related adverse events pre-specified in the protocol

    Time frame: up to 24 hours after surgery, up to 48 hours

  5. Phase 2: Time to Readiness for Surgery

    Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery.

    Time frame: Intraoperative

  6. Phase 2:Maximum Level of Sensory Block

    Sensorial block will be verified by bilateral Pinprick test using a 20-G hypodermic needle and will be recorded. Pinprick sensation will be scored as being present (score 1) or absent (score 0). Onset of sensory block is defined as an absent touch sensation (score 0)

    Time frame: Intraoperative

  7. Phase 2: Time to Sensory Block

    Time to maximum level of sensory block

    Time frame: Intraoperative

  8. Phase 2: Time to Regression of Spinal Block

    Time period from spinal injection (time 0 h) to the time when the Bromage score returns to 0 and sensitive perception returns to S1. Bromage scale: I - Free movement of legs and feet II - Just able to flex knees with free movement of feet III - Unable to flex knees, but with free movement of feet IV - Unable to move legs or feet

    Time frame: from readiness for surgery,then every 10 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 30 min until regression of spinal block

  9. Phase 2: Vital Signs

    Systolic and Diastolic Blood Pressure (mmHg)

    Time frame: at screening, at baseline (before the spinal injection) and at end of the study (Day 6).

  10. Phase2: Concomitant Medications

    record the concomitant medications intaked during the study

    Time frame: at screening, at baseline until the end of the study (Day 6)

  11. Phase 2: SpO2

    Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.

    Time frame: at screening, at baseline (before the spinal injection) and at the end of the study (day 6)

  12. Phase 2: ECG

    Electrocardiography is the process of producing an electrocardiogram (ECG), it is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin.

    Time frame: screening, baseline and end of study (Day 6±1)

07

Results

Posted Jun 1, 2021

Participant flow

First Part
Participant flow — First Part
Milestone60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Started3330
Completed3330
Not completed0000
Second Part
Participant flow — Second Part
Milestone60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Started15151515
Completed15151515
Not completed0000

Outcome measures

PrimaryPhase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol

Phase 1: Number of participants with treatment evaluation and confirmation of the safety of the three doses of paracetamol 3% solution administered in the total number of patients enrolled

Time frame:
In the first 24 hours, in the first 48 hours and at day 7±1
Reported as:
Number · participants
Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol
participants60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)
Adverse event related000
Adverse event not related116
Serious adverse event000
PrimaryPhase 2: Pain Intensity

Phase 2: Pain intensity at rest evaluated as VAS scores ( 0-100 mm visual analogue scale : 0 is the absence pain and 100 is the maximum pain sensation)

Time frame:
baseline (0 h), 1, 6, 9, 12, 15, 24, and 48 h after anaesthetic IT injection and at discharge
Reported as:
Mean · units on a scale
Phase 2: Pain Intensity
units on a scale60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
baseline11.9 ± 15.517.3 ± 15.624.5 ± 19.510.7 ± 13.4
1 hour after anaesthetic0 ± 00 ± 00 ± 00 ± 0
6 hours after anaesthetic21.5 ± 22.232.2 ± 2520.3 ± 25.342.3 ± 31.5
9 hours after anaesthetic21.6 ± 1813.6 ± 11.617.3 ± 2426.3 ± 22.3
12 hours after anaesthetic13.1 ± 16.510.1 ± 8.611.2 ± 17.517.9 ± 16.7
15 hours after anaesthetic15.4 ± 16.710.2 ± 10.210.6 ± 13.820.5 ± 21.5
24 hours after anaesthetic11.4 ± 10.79.5 ± 8.913.6 ± 14.916 ± 18.3
48 hours after anaesthetic6.1 ± 8.63.2 ± 6.67.7 ± 12.98.7 ± 11.6
Discharge2.5 ± 3.74.1 ± 4.84.8 ± 6.88.0 ± 9.6
SecondaryPhase 2: Morphine

Phase 2: Total morphine use

Time frame:
At 24 and 48 h after anaesthetic IT injection and entire study period, up to 7 days
Reported as:
Mean · mg
Phase 2: Morphine
mg60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
first 24 hours14.1 ± 10.412.6 ± 4.522.8 ± 14.714.3 ± 7.4
first 48 hours24.5 ± 19.715.8 ± 5.133.5 ± 21.521 ± 12.8
entire study period24.8 ± 19.715.8 ± 5.133.8 ± 21.421.1 ± 13
SecondaryPhase 2: Time to First Morphine Use

Phase 2: Time to first morphine use (minutes)

Time frame:
Postoperative, up to 48 hours after end of surgery
Reported as:
Median · minutes
Phase 2: Time to First Morphine Use
minutes60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Phase 2: Time to First Morphine Use351 (275 to 503)236 (181 to 322)318 (184 to 415)279 (169 to 313)
SecondaryPhase 2: Number of Participants With Need for Supplemental Analgesia

Phase 2: Need for supplementary analgesia, other than the planned morphine PCA

Time frame:
Postoperative, up to 48 hours after end of surgery
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Need for Supplemental Analgesia
Participants60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Phase 2: Number of Participants With Need for Supplemental Analgesia9111110
SecondaryPhase 2: Morphine-related Adverse Events

Percentage of subjects experiencing during the study the morphine-related adverse events pre-specified in the protocol

Time frame:
up to 24 hours after surgery, up to 48 hours
Reported as:
Count of participants · Participants
Phase 2: Morphine-related Adverse Events
Participants60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Phase 2: Morphine-related Adverse Events1616
SecondaryPhase 2: Time to Readiness for Surgery

Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery.

Time frame:
Intraoperative
Reported as:
Median · minutes
Phase 2: Time to Readiness for Surgery
minutes60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Phase 2: Time to Readiness for Surgery9 (5 to 16)10 (4 to 10)10 (5 to 11)8 (5 to 12)
SecondaryPhase 2:Maximum Level of Sensory Block

Sensorial block will be verified by bilateral Pinprick test using a 20-G hypodermic needle and will be recorded. Pinprick sensation will be scored as being present (score 1) or absent (score 0). Onset of sensory block is defined as an absent touch sensation (score 0)

Time frame:
Intraoperative
Reported as:
Number · participants
Phase 2:Maximum Level of Sensory Block
participants60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
T10000
T20000
T30000
T40201
T52100
T64433
T71216
T8771028
T90202
T102010
T111000
SecondaryPhase 2: Time to Sensory Block

Time to maximum level of sensory block

Time frame:
Intraoperative
Reported as:
Median · minutes
Phase 2: Time to Sensory Block
minutes60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Phase 2: Time to Sensory Block18 (13 to 20)15 (9 to 20)15 (13 to 20)17 (10 to 23)
SecondaryPhase 2: Time to Regression of Spinal Block

Time period from spinal injection (time 0 h) to the time when the Bromage score returns to 0 and sensitive perception returns to S1. Bromage scale: I - Free movement of legs and feet II - Just able to flex knees with free movement of feet III - Unable to flex knees, but with free movement of feet IV - Unable to move legs or feet

Time frame:
from readiness for surgery,then every 10 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 30 min until regression of spinal block
Reported as:
Median · minutes
Phase 2: Time to Regression of Spinal Block
minutes60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
Phase 2: Time to Regression of Spinal Block285 (260 to 345)246 (228 to 280)265 (245 to 303)280 (232 to 302)
SecondaryPhase 2: Vital Signs

Systolic and Diastolic Blood Pressure (mmHg)

Time frame:
at screening, at baseline (before the spinal injection) and at end of the study (Day 6).
Reported as:
Mean · mmHg
Phase 2: Vital Signs
mmHg60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
systolic Blood Pressure at screening137 ± 20.4144.6 ± 20.5148.5 ± 14.7147.7 ± 15.7
systolic Blood Pressure at baseline145.5 ± 13.6146.3 ± 19.2138.7 ± 10.5144.8 ± 12.3
systolic Blood Pressure at end of the study (day6)130 ± 14.6130.3 ± 11.3133.5 ± 10.2138.1 ± 14.5
Diastolic Blood Pressure at screening87.1 ± 11.385.7 ± 790.9 ± 8.287 ± 5.1
Diastolic Blood Pressure at baseline83 ± 8.878.9 ± 10.377.8 ± 1085.9 ± 5.8
Diastolic Blood Pressure at end of the study (day6)79.5 ± 10.878.2 ± 7.579 ± 6.883.1 ± 9.3
SecondaryPhase2: Concomitant Medications

record the concomitant medications intaked during the study

Time frame:
at screening, at baseline until the end of the study (Day 6)
Reported as:
Number · participants
Phase2: Concomitant Medications
participants60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
heparin group15151515
Second-generation cephalosporins15151515
Solutions affecting the electrolyte balance15151515
Direct factor Xa inhibi15151415
Amino acids14131215
propofol11131314
Adrenergic and dopaminergic agents10111212
Propionic acid derivatives78106
Pyrazolones47119
Acetic acid derivatives and related substances6788
Osmotically acting laxatives1363
Proton pump inhibitors2443
Serotonin (5HT3) antagonists1624
Benzodiazepine derivatives2042
ANTIEMETICS AND ANTINAUSEANTS1213
Other opioids1112
Platelet aggregation inhibitors excl. heparin1101
Angiotensin II antagonists,1100
Natural opium alkaloids0011
SecondaryPhase 2: SpO2

Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.

Time frame:
at screening, at baseline (before the spinal injection) and at the end of the study (day 6)
Reported as:
Mean · Oxygen Saturation percentage
Phase 2: SpO2
Oxygen Saturation percentage60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
screening97.93 ± 0.5998 ± 0.5398.27 ± 0.7097.80 ± 0.77
baseline97.27 ± 1.0397.07 ± 1.0397.33 ± 1.1896.87 ± 1.36
end of the study (day 6)97.73 ± 1.0397.53 ± 0.8397.8 ± 0.7797.6 ± 0.74
SecondaryPhase 2: ECG

Electrocardiography is the process of producing an electrocardiogram (ECG), it is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin.

Time frame:
screening, baseline and end of study (Day 6±1)
Reported as:
Count of participants · Participants
Phase 2: ECG
Participants60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
screening — normal1091111
screening — Abnormal, Not Clinically Significant5644
screening — Abnormal, Clinically Significant0000
baseline — normal13111112
baseline — Abnormal, Not Clinically Significant2443
baseline — Abnormal, Clinically Significant0000
end of study — normal12131112
end of study — Abnormal, Not Clinically Significant3243
end of study — Abnormal, Clinically Significant0000

Adverse events

Collected over Clinical study duration (7 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
60 mg Paracetamol 3% (2 mL)0/18 (0%)0/18 (0%)8/18 (44.4%)
90 mg Paracetamol 3% (3 mL)0/18 (0%)0/18 (0%)10/18 (55.6%)
120 mg Paracetamol 3% (4mL)0/18 (0%)0/18 (0%)13/18 (72.2%)
Phase II Only: Saline Solution 0.9%0/15 (0%)0/15 (0%)11/15 (73.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
Event60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%
hypotensionVascular disorders6/183/188/185/15
procedural nauseaInjury, poisoning and procedural complications1/187/183/185/15
postprocedural constipationInjury, poisoning and procedural complications0/183/186/184/15
urinary retention postoperativeInjury, poisoning and procedural complications1/180/184/181/15
headacheNervous system disorders1/181/183/180/15
procedural vomitingInjury, poisoning and procedural complications0/182/181/181/15
bradycardiaCardiac disorders0/181/181/181/15
atrial fibrillationCardiac disorders0/180/180/181/15
antiementic supportive careSurgical and medical procedures0/180/180/181/15
joint dislocationInjury, poisoning and procedural complications0/181/180/180/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%Total
Mean66.9 ± 6.765.1 ± 7.962.3 ± 9.365.1 ± 7.764.8 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%Total
Female8134631
Male10514938
Race (NIH/OMB)
Race (NIH/OMB)(Participants)60 mg Paracetamol 3% (2 mL)90 mg Paracetamol 3% (3 mL)120 mg Paracetamol 3% (4mL)Phase II Only: Saline Solution 0.9%Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1818181569
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Claudio Camponovo
    Gravesano, Lugano CH-6929, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Feb 2019 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2021, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2015
First posted
Jan 13, 2016
Start
Nov 2016
Primary completionActual
Feb 2019
CompletionActual
Feb 2019
Results first posted
Jun 1, 2021
Last update
Oct 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02654860
Lead sponsor
Sintetica SA
Collaborators
Cross S.A.
Responsible party
Sponsor
First posted
Jan 13, 2016
Start date
Nov 2016
Primary completion
Feb 2019
Completion
Feb 2019
Results posted
Jun 1, 2021
Last update
Oct 27, 2021

Study contacts

Claudio Camponovo, MD
principal investigator · Department of Anaesthesiology,Clinica Ars Medica,Via Cantonale, CH-6929 Gravesano, Switzerland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion